Accelerated Pharma Filed Terms, Nasdaq: ACCP

Developing a chemotherapy optimized by genomic screening.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on utilizing our genomic technology to (i) enhance the development of pre-existing pharmaceutical products for the treatment of various cancer indications, (ii) prospectively identify patients that may respond to such pharmaceutical products and (iii) commercialize such pharmaceutical products for sale in various markets. Our lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.
more less
IPO News for Accelerated Pharma
more
IPO Data
IPO File Date 10/11/2016
Offer Price
Price Range $4.00 - $6.00
Offer Shares (mm) 1.5
Deal Size ($mm) $8
IPO Data
IPO Date
Offer Price
Price Range $4.00 - $6.00
Offer Shares (mm) 1.5
Deal Size ($mm) $8
Underwriters
more
Company Data
Headquarters Westport, CT
Founded 2014
Employees 7
Website www.apipharmaceuticals.com